Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3252W HIGH $11.08
Volume
12.80 K
Value Traded
206.47 K
Short % Float
0.64%
-16.15%Week
-32.16%1 Month
-37.5%3 Month
-51.26%6 Month
-99.92%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.74 M
EPS (TTM)
-4.81
P/E Ratio
-
Ent. Value
3.54 M
Total Shares
2.77 M
Float Shares
2.36 M
Insiders
15.46%
Institutions
14.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PCSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Processa Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Processa Pharmaceuticals, Inc.
324Total events
5Upcoming
64Tier-1 (high impact)
2013 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Concurrent private placement financing of approximately $200 million
▲Enrollment CompleteNGC-CapTrial
Completed enrollment of 20th patient for formal interim analysis
advanced or metastatic breast cancersource ↗
◆Interim AnalysisNGC-CapTrial
Formal interim analysis safety and efficacy data expected
advanced or metastatic breast cancersource ↗
◆Interim AnalysisPCS6422Trial
Formal interim analysis of first 20 patients expected
advanced or metastatic breast cancersource ↗
◆Enrollment CompletePCS6422Trial
Enrollment of final patient for 20-patient interim analysis expected by end of Q1 2026
advanced or metastatic breast cancersource ↗
▲Enrollment CompletePCS6422Trial
Enrollment of 19 patients completed for preliminary analysis
advanced or metastatic breast cancersource ↗
◆Poster PresentationPCS499Presentation
Poster presentation at ASN Kidney Week 2025
Focal Segmental Glomerulosclerosis (FSGS)source ↗
◆Enrollment UpdateNGC-CapTrial
NGC-Cap Phase 2 trial actively enrolling patients
metastatic breast cancersource ↗
◆Topline ReadoutNGC-CapClinical Data
Initial data from NGC-Cap Phase 2 trial expected in H2 2025
metastatic breast cancersource ↗
▲Partnership / LicensePCS12852Corporate
Processa signs binding term sheet granting Intact exclusive option to license PCS12852
gastroparesissource ↗
◆Oral PresentationPresentation
Processa Pharmaceuticals to attend BIO International Convention 2025
◆Topline ReadoutNGC-CapClinical Data
Initial data from Phase 2 trial expected mid-2025
advanced or metastatic breast cancersource ↗
◆Poster PresentationPCS6422Presentation
Safety and Efficacy of Eniluracil + Capecitabine (6422 + Cap) in Phase 1b Trial
cancersource ↗
◆Poster PresentationPCS11TPresentation
Preclinical Project Optimus Dose Escalation of SN-38 Pro-Drug PCS11T
cancersource ↗
◆Oral PresentationPresentation
Dr. David Young presents at World Orphan Drug Congress USA 2025
◆Topline ReadoutNGC-CapClinical Data
Interim data from Phase 2 trial of NGC-Cap expected in second half of 2025
advanced or metastatic breast cancersource ↗
◆Oral PresentationPresentation
Corporate overview presentation at MedInvest Biotech and Pharma Investor Conference
◆Oral PresentationPresentation
Corporate overview presentation at 2025 BIO CEO & Investor Conference
●IND Enabling CompleteNGC-IriPreclinical
IND-enabling toxicology studies for NGC-Iri expected in 2025
cancer (irinotecan-sensitive types)source ↗
▲First Patient DosedNGC-CapTrial
First patient dosed in Phase 2 trial of NGC-Cap in metastatic breast cancer
advanced or metastatic breast cancersource ↗
▲First Patient DosedNGC-CapTrial
First patient dosed in Phase 2 trial of NGC-Cap for metastatic breast cancer
advanced or metastatic breast cancersource ↗
◆Oral PresentationPresentation
ESMO Congress 2024 meetings with clinicians and potential partners
◆Oral PresentationPresentation
H.C. Wainwright 26th Annual Global Investment Conference presentation
▲Preclinical PoCNGC-IriPreclinical
Positive preclinical data for NGC-Iri showing improved tumor accumulation and reduced side effects vs irinotecan and Onivyde
solid tumors (melanoma xenograft model)source ↗
▲Preclinical PoCNGC-IriPreclinical
Positive preclinical data for NGC-Iri showing greater tumor SN-38 accumulation vs irinotecan and Onivyde
cancer (irinotecan-sensitive types)source ↗
▲Trial InitiationNGC-CapTrial
Initiated Phase 2 trial of NGC-Cap in breast cancer
metastatic or advanced breast cancersource ↗
▲IND ClearanceNGC-CapIND
FDA clearance of IND for Phase 2 trial of NGC-Cap in breast cancer
advanced or metastatic breast cancersource ↗
◆Trial InitiationNGC-CapTrial
Phase 2 trial initiation in breast cancer expected in Q3 2024
breast cancersource ↗
▲First Patient DosedNGC-CapTrial
First patient dosed expected in Q3 2024
advanced or metastatic breast cancersource ↗
▲IND ClearanceNGC-CapIND
FDA cleared IND for NGC-Cap Phase 2 trial in breast cancer
metastatic or advanced breast cancersource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: $12.9 million expected to fund operations into Q3 2024
▲Trial CompletionNGC-CapTrial
Phase 1b trial completed
Stage III or IV gastrointestinal tract cancersource ↗
▲Topline ReadoutNGC-CapClinical Data
Positive preliminary efficacy results from Phase 1b trial
Stage III or IV gastrointestinal tract cancersource ↗
◆Safety Data UpdatePCS6422Clinical Data
Safety profile assessment across all cohorts
colorectal, pancreatic, and other solid tumor cancerssource ↗
◆Dose Finding UpdatePCS6422Trial
Phase 2 dose regimen finalization
colorectal, pancreatic, and other solid tumor cancerssource ↗
●IND SubmissionPCS6422IND
Filing of Phase 2 study to IND
colorectal, pancreatic, and other solid tumor cancerssource ↗
◆Trial InitiationPCS6422Trial
Start of patient enrollment in Phase 2 study
colorectal, pancreatic, and other solid tumor cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How PCSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | PCS6422+Cap (NGC-Cap) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$4M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
0.8x
rNPV / MCap
Top 66%
Micro Cap(rank 435 of 658)
Percentile Rank
Processa Pharmaceuticals, Inc. faces pipeline headwinds (31/100), with $1.2B risk-adjusted pipeline value, led by VT7208 in Multiple Sclerosis (Phase 1), across $53B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VT7208 Small moleculeNCT07085507 | Multiple Sclerosis | Phase 1 | RECRUITING | 100 | Dec 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PCSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NGC-Cap | advanced or metastatic breast cancer | Phase 2 | 2026-01-13 | increases exposure to capecitabine’s cancer-killing metabolites; maintaining a safety profile comparable to standard capecitabine monotherapyRead More | Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ng George KDirector, Officer (Chief Executive Officer) | Option | 1,600 17,092 held | $0.00 | 08/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PCSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PCSA for Q2 2026. | ||||
PCSA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PCSA ranks across every disease it competes in
Competitive Position is a premium feature
See how PCSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPCSA News
PCSAProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences where Sheila Gujrathi, M.D., will present. The company is focused on advancing its lead program VT-7208, a BTK inhibitor for immune-mediated diseases. Following the acquisition of Vidya Therapeutics, Processa aims to progress its clinical programs towards Phase 2 studies.
Read more →PCSA▼ -33.4%on this news
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
Processa Pharmaceuticals has announced the acquisition of Vidya Therapeutics, which includes the promising BTK inhibitor VT-7208. This acquisition is complemented by a $200 million private placement financing aimed at advancing VT-7208 through key clinical milestones in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. The funding is expected to sustain operations until the second half of 2029.
Read more →PCSAProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals will attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO George Ng and Chief Business Officer Patrick Lin will hold one-on-one meetings to discuss their clinical pipeline, particularly the Phase 2 study of NGC-Cap for advanced breast cancer. Preliminary data indicate that NGC-Cap enhances exposure to effective metabolites while maintaining safety.
Read more →PCSA▲ +10.2%on this news
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Processa Pharmaceuticals has completed the enrollment of 20 patients for a formal interim analysis in its Phase 2 study of NGC-Cap, a combination treatment for advanced breast cancer. This analysis aims to compare the safety and efficacy of NGC-Cap against standard capecitabine therapy. Results are anticipated in the first quarter of 2026, which will guide future study design and dose optimization.
Read more →PCSA▼ -41.6%on this news
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals provided an update on its Phase 2 study of NGC-Cap, a combination of PCS6422 and capecitabine for metastatic breast cancer. Preliminary data from 16 of 19 patients indicate that NGC-Cap enhances exposure to effective cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine therapy. The full interim analysis is expected in early 2026.
Read more →PCSAProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals announced that its abstract for the adaptive Phase 2/3 study of PCS499 in patients with FSGS has been accepted for presentation at ASN Kidney Week 2025. The study aims to optimize dosing and address the urgent need for effective therapies in this rare kidney disease. PCS499 has demonstrated a favorable safety profile, potentially allowing for greater therapeutic benefits compared to existing treatments.
Read more →PCSAProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals has announced a strategic investment and is exploring cryptocurrency treasury strategies to enhance financial flexibility and support its clinical development programs. The company aims to diversify its capital base while maintaining compliance with regulatory standards. CEO George Ng emphasized the commitment to delivering meaningful therapies for cancer patients and optimizing outcomes for shareholders.
Read more →PCSAProcessa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals has provided an update on its product pipeline and business activities, emphasizing its focus on oncology assets with strong differentiation. The company is actively enrolling patients in its Phase 2 clinical trial for metastatic breast cancer and anticipates sharing initial data in the second half of 2025. CEO George Ng will discuss the strategic pipeline realignment in an upcoming investor webinar.
Read more →PCSA▼ -42.2%on this news
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals announced the pricing of a public offering of 28 million shares at $0.25 each, aiming to raise $7 million. The proceeds will be used to continue the Phase 2 clinical trial for NCG-Cap and for general corporate purposes. The offering is expected to close around June 18, 2025.
Read more →PCSA▲ +15.5%on this newsshared move
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals has signed a binding term sheet with Intact Therapeutics, granting them the exclusive option to license PCS12852, a promising treatment for gastroparesis. The agreement includes a $2.5 million option fee and potential milestone payments exceeding $452 million. PCS12852 has shown strong safety and efficacy in clinical trials, positioning it as a leading candidate for gastrointestinal motility disorders.
Read more →PCSA▼ -24.9%on this newsshared move
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals will participate in the 2025 BIO International Convention in Boston, where its leadership will meet with potential partners and investors. The focus will be on the company's Next Generation Cancer therapies, particularly NGC-Cap, which is currently in a Phase 2 trial for metastatic breast cancer. This event provides an opportunity to showcase their clinical advancements and regulatory science approach.
Read more →PCSAProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, showcasing their Next Generation Cancer drug candidates. The abstracts detail advancements in clinical and preclinical studies, including data on the safety and efficacy of NGC-Cap and the dose escalation of PCS11T. This reflects the company's commitment to addressing unmet needs in oncology.
Read more →PCSAProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals announced that Dr. David Young will present at the World Orphan Drug Congress USA 2025. His presentation will focus on applying FDA's Project Optimus principles to enhance drug efficacy and safety for rare diseases. This aligns with Processa's mission to develop next-generation cancer therapies.
Read more →PCSA▼ -5.1%on this news
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals will present at the MedInvest Biotech and Pharma Investor Conference on March 28, 2025. The company aims to showcase its innovative cancer therapies that enhance efficacy and safety. Management will also engage in one-on-one meetings with investors during the event. The presentation will be accessible on the company's website.
Read more →PCSA▲ +10.4%on this news
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals will present at the 2025 BIO CEO & Investor Conference on February 11, 2025. The company aims to showcase its innovative approach to developing next-generation cancer therapies that enhance safety and efficacy. Management will also hold one-on-one meetings with investors during the event, promoting further engagement and collaboration.
Read more →PCSA▲ +10.6%on this news
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has successfully closed a $5 million public offering priced at-the-market under Nasdaq rules. The offering included participation from the company's CEO, board members, and institutional investors. Gross proceeds are aimed at advancing their pipeline of next-generation chemotherapeutic drugs. The registration statement for the offering was declared effective by the SEC shortly before the closing date.
Read more →PCSAProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has announced the pricing of a $5 million public offering, which includes 8,050,672 shares of common stock and accompanying Series A and B warrants. The offering is led by the company's CEO and various board members, with institutional investor involvement. The completion of the offering is subject to customary closing conditions and is expected to close by January 29, 2025. Additionally, the company will seek stockholder approval for the issuance of shares related to the warrants within 90 days post-offering.
Read more →PCSAProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
Processa Pharmaceuticals has marked significant progress by dosing the first patient in its Phase 2 clinical trial for NGC-Cap to treat metastatic breast cancer. The company reported positive data from preclinical studies for its NGC-Iri candidate, suggesting improved efficacy compared to existing therapies. However, the company has also faced financial challenges, with a net loss increasing to $3.4 million for Q3 2024 and reduced cash reserves. Processa remains focused on enhancing the safety and effectiveness of cancer treatments through its innovative drug development strategies.
Read more →PCSAProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Processa Pharmaceuticals has announced the dosing of the first patient in a Phase 2 clinical trial for NGC-Cap, targeting metastatic breast cancer. The trial aims to evaluate the safety and efficacy of NGC-Cap compared to capecitabine. With plans to activate around 30 clinical sites worldwide, this study could significantly advance treatment options in a field with a high need for improved therapies. Interim results are expected in mid-2025, building on positive findings from earlier trials.
Read more →About Processa Pharmaceuticals, Inc.
Headquarters601 21ST STREET, SUITE 300, VERO BEACH, FL, 32960
BIOPHARMAWATCH ELITE PLUS
Trade the next PCSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime